Daré Bioscience, Inc. (DARE)
0.8428
-0.01
(-0.96%)
USD |
NASDAQ |
Oct 02, 16:00
0.8353
-0.01
(-0.89%)
After-Hours: 20:00
Daré Bioscience Enterprise Value : 6.932M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 6.932M |
| October 01, 2026 | 7.056M |
| September 30, 2026 | 7.091M |
| September 29, 2026 | 6.510M |
| September 28, 2026 | 5.524M |
| September 25, 2026 | 5.911M |
| September 24, 2026 | 5.380M |
| September 23, 2026 | 6.395M |
| September 22, 2026 | 7.041M |
| September 21, 2026 | 6.434M |
| September 18, 2026 | 6.044M |
| September 17, 2026 | 5.491M |
| September 16, 2026 | 5.152M |
| September 15, 2026 | 5.222M |
| September 14, 2026 | 5.316M |
| September 11, 2026 | 4.856M |
| September 10, 2026 | 4.843M |
| September 09, 2026 | 5.017M |
| September 08, 2026 | 4.963M |
| September 04, 2026 | 5.084M |
| September 03, 2026 | 4.964M |
| September 02, 2026 | 5.372M |
| September 01, 2026 | 5.830M |
| August 31, 2026 | 5.691M |
| August 28, 2026 | 5.296M |
| Date | Value |
|---|---|
| August 27, 2026 | 5.352M |
| August 26, 2026 | 5.533M |
| August 25, 2026 | 6.596M |
| August 24, 2026 | 6.305M |
| August 21, 2026 | 6.584M |
| August 20, 2026 | 6.422M |
| August 19, 2026 | 6.652M |
| August 18, 2026 | 5.80M |
| August 17, 2026 | 6.437M |
| August 14, 2026 | 8.254M |
| August 13, 2026 | 14.93M |
| August 12, 2026 | 15.99M |
| August 11, 2026 | 15.99M |
| August 10, 2026 | 14.78M |
| August 07, 2026 | 15.38M |
| August 06, 2026 | 14.32M |
| August 05, 2026 | 14.47M |
| August 04, 2026 | 14.47M |
| August 03, 2026 | 13.56M |
| July 31, 2026 | 12.65M |
| July 30, 2026 | 12.96M |
| July 29, 2026 | 11.74M |
| July 28, 2026 | 12.12M |
| July 27, 2026 | 14.17M |
| July 24, 2026 | 13.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Elite Pharmaceuticals, Inc. | 212.92M |
| Eton Pharmaceuticals, Inc. | 1.569B |
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.983M |
| Revenue (Quarterly) | 0.1875M |
| Total Expenses (Quarterly) | 3.170M |
| EPS Diluted (Quarterly) | -0.2003 |
| Gross Profit Margin (Quarterly) | -294.5% |
| Profit Margin (Quarterly) | -1.59K% |
| Earnings Yield | -93.21% |
| Normalized Earnings Yield | -93.21 |